Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus
Bilsborrow JB, Doherty E, Tilstam PV, Bucala R. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. Expert Opinion On Therapeutic Targets 2019, 23: 733-744. PMID: 31414920, PMCID: PMC6800059, DOI: 10.1080/14728222.2019.1656718.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArthritis, RheumatoidHumansIntramolecular OxidoreductasesLupus Erythematosus, SystemicMacrophage Migration-Inhibitory FactorsMicePolymorphism, GeneticPrecision MedicineConceptsMacrophage migration inhibitory factorSystemic lupus erythematosusRheumatoid arthritisMigration inhibitory factorLupus erythematosusMIF inhibitorsMIF inhibitionAutoimmune diseasesRole of MIFInhibitory factorPathogenesis of RARefractory autoimmune diseasesHigh expressionPleiotropic inflammatory cytokineClinical trial dataPrecision medicine approachGlucocorticoid dependenceInflammatory cytokinesAdaptive immunityTherapeutic targetClinical developmentSmall molecule inhibitorsTrial dataTherapeutic potentialErythematosus